Private Label Tranexamic Acid SPF 50 Sunscreen Manufacturer Low MOQ

For a finished, labeled private label tranexamic acid SPF 50 sunscreen, the realistic low MOQ range is 500 to 1,000 units per SKU. Some manufacturers may quote 300 units, but this is rarely economical once you factor in the cost of SPF efficacy testing, which is mandatory before any claim can appear on labeling. SPF testing through an ISO-accredited lab typically costs $1,500 to $3,500 per formula and cannot be spread across a tiny batch without inflating per-unit costs to unsustainable levels for most brands. The MOQ is also influenced by several moving variables. Fill size matters: a 30 mL tube may have a lower MOQ than a 50 mL airless pump because the former is more commonly run on a co-packer's existing line. The UV filter system affects it too — mineral formulas (zinc oxide-based) often require specialized high-shear mixing equipment, and factories with that equipment tend to book it in longer runs. Tranexamic acid concentration also plays a role; higher concentrations (4–5%) require tighter batch-to-batch QC, which some smaller toll manufacturers prefer to handle in larger runs to amortize QC costs. Regionally, Asian contract manufacturers (South Korea, China, Taiwan) frequently offer lower MOQs — sometimes 300 to 500 units — because their production lines are optimized for faster format changes and smaller cosmetic batches. However, if you're selling into the US market, ensure any Asian manufacturer has US FDA OTC drug establishment registration, as SPF 50 sunscreens are regulated as OTC drugs in the US. EU-focused brands have more flexibility since SPF products are cosmetics there, and EU-based or EU-exporting Asian manufacturers can be more MOQ-flexible. If your target launch quantity is under 500 units, consider starting with a white-label (off-the-shelf formula) tranexamic acid SPF base that a manufacturer already owns, then customizing fragrance, packaging, and claims. This can drop effective MOQ to 200–300 units because the manufacturer skips the custom formulation and stability investment. You can always transition to a custom formula at your second or third production run once sales validate the SKU. AJ Cosmo Labs is a good place to filter manufacturers specifically by their SPF MOQ capability before reaching out, so you don't spend weeks in conversations with factories whose minimums are 10 times your target.

The total landed cost of private labeling a tranexamic acid SPF 50 sunscreen has several distinct buckets, and founders often underestimate total spend by focusing only on the per-unit manufacturing cost. Formulation and development: If you're commissioning a custom formula, expect to pay $1,500 to $5,000 for a cosmetic chemist's development retainer. Some manufacturers waive this fee if your order volume is large enough, but at low MOQ (under 1,000 units), you'll almost always pay it. If you choose an existing white-label formula and simply add your label, development cost drops to zero or a nominal customization fee of $200 to $500. Stability and SPF testing: In the US, SPF efficacy testing (in-vivo per FDA OTC monograph) costs $2,000 to $4,000. In the EU, in-vitro testing per ISO 24444 runs $800 to $2,500. Accelerated stability testing (12 weeks minimum) adds $500 to $1,500. If you use an existing stable formula from the manufacturer's portfolio and they already hold the test data, these costs may be shareable or already amortized. Per-unit manufacturing cost: At 500–1,000 units, expect $6 to $12 per unit for the filled and capped product, excluding your outer packaging and labels. At 1,000–5,000 units this drops to $3.50 to $7. At 5,000–20,000 units you're typically at $1.80 to $4.00. Tranexamic acid at 2–5% adds roughly $0.30 to $0.80 per unit to raw material cost depending on concentration and gram weight. Packaging: Primary packaging (tubes, airless pumps, jars) sourced independently runs $0.40 to $2.50 per unit at low MOQ. Labels or custom-printed packaging add $0.10 to $0.80 depending on material and print method. If your manufacturer handles procurement, they often mark up 15–25%. Regulatory setup: First-time US brands launching an OTC sunscreen need an NDC number (free from FDA but requires a facility registration) and a proper Drug Facts panel designed by someone familiar with 21 CFR 201.66. Expect $300 to $800 in labeling compliance consulting if you do it yourself and $1,000 to $3,000 if outsourced. EU brands need a CPSR from a qualified safety assessor, which costs $800 to $2,500. Adding it all up, a first run of 500 units with a custom formula, US OTC compliance, and independent SPF testing can easily reach $15,000 to $25,000 in total investment before you sell a single unit. A white-label approach with the same 500-unit run can bring that down to $6,000 to $10,000. Planning these buckets before you begin supplier conversations is critical, and the briefing tools inside AJ Cosmo Labs help you lay out your full budget so manufacturers can respond with accurate scopes.

The full timeline from initial brief to first sellable units typically runs 14 to 22 weeks for a custom-formulated tranexamic acid SPF 50 sunscreen in the US market. Here's how that breaks down stage by stage. Weeks 1–3: Supplier selection, NDA execution, and brief alignment. This is often the stage founders underestimate most. Finding the right manufacturer, vetting their credentials, negotiating terms, and finalizing your formula brief can easily take two to four weeks if you don't have warm introductions. Using a platform like AJ Cosmo Labs compresses this stage significantly because you're reaching pre-vetted manufacturers who respond to structured briefs. Weeks 4–7: Formula development. Your cosmetic chemist or the manufacturer's in-house formulator develops the tranexamic acid SPF 50 base, adjusts for texture, finish, and UV filter system, and produces initial lab samples. This phase includes internal compatibility screening — tranexamic acid is water-soluble and must be incorporated into an appropriate phase without destabilizing the emulsion or interacting negatively with UV filters like avobenzone. Weeks 8–11: Prototype review and iteration. You review samples, request adjustments (color, scent, skin feel, white cast), and the lab iterates. Two to three rounds of revision is normal. Budget for this in both time and your development retainer. Weeks 12–15: Stability and SPF testing. Accelerated stability (40°C/75% RH for 12 weeks minimum) runs in parallel with SPF efficacy testing. Many manufacturers will begin production preparation during this phase if you've signed a purchase order, to save time. In the EU, in-vitro SPF testing is faster (4–6 weeks); US in-vivo testing takes longer (8–12 weeks) and must be run at an FDA-compliant testing site. Weeks 16–18: Regulatory documentation, label finalization, and production scheduling. Drug Facts panel sign-off for US, CPSR for EU, artwork final approval, and scheduling your production slot. Weeks 19–22: Bulk production, filling, capping, labeling, QC release, and shipment. A 1,000-unit run typically takes 1–2 weeks on the fill line once the slot is active, but QC hold and release can add another 1–2 weeks. If you use a white-label formula the manufacturer already has stable SPF test data for, you can collapse the formulation, iteration, and stability phases entirely and hit a 8–12 week total timeline. The tradeoff is less formula differentiation. Most experienced founders launching their first SPF SKU take the white-label route to hit a faster launch, then invest in a custom formula for their second run.

Tranexamic acid is a well-established ingredient in dermatology, originally used as a hemostatic agent but now widely adopted in cosmetic skincare for its ability to inhibit the interaction between keratinocytes and melanocytes, reducing UV-triggered melanin synthesis. When combined with a broad-spectrum SPF 50 base, it creates a compelling dual-action product: the UV filters block the UV radiation that triggers hyperpigmentation, while the tranexamic acid addresses the biochemical cascade that leads to dark spot formation even in the presence of imperfect UV protection. For cosmetic use, the effective concentration range is 2% to 5%. The majority of published clinical data on topical tranexamic acid for melasma and post-inflammatory hyperpigmentation uses a 2% to 3% concentration applied twice daily over 8–12 weeks. At 5%, some studies show faster visible improvement but with a diminishing returns curve above 3%. For an SPF product used in the morning only, 3% is a common and defensible formulation target. Stability is the primary formulation challenge. Tranexamic acid is water-soluble, pH-sensitive, and must be incorporated into the water phase of an emulsion. It is relatively stable at pH 5.5–7.0, which aligns well with most sunscreen emulsion systems. However, it can interact with anionic polymers (like carbomer) and some chelating agents, so your cosmetic chemist must screen for compatibility carefully. At higher temperatures (above 45°C), some degradation can occur, making accelerated stability testing especially important for this active. From a safety standpoint, tranexamic acid has a strong tolerability profile in topical applications. It is non-irritating at cosmetic concentrations for the vast majority of skin types, including sensitive skin, which makes it a strong pairing with SPF for daily use without concerns about phototoxicity — a limitation of some other brightening actives like retinoids or AHAs. The EU limits tranexamic acid in cosmetics to 2% under Annex III of EC 1223/2009, which is the primary regulatory consideration for EU-market formulations. For a US market product, tranexamic acid is not an FDA-recognized sunscreen active and plays no role in the OTC drug portion of the product label. It sits in the inactive or cosmetic ingredient portion of a sunscreen OTC drug product and is listed in the inactive ingredients section of the Drug Facts panel. This is a nuance many first-time SPF founders miss, and it matters for how you word claims. You can market the brightening benefit in your product description and marketing copy, but the Drug Facts panel is governed by the OTC monograph and does not accommodate cosmetic actives claims. When evaluating manufacturers for this formula type, ask specifically whether their cosmetic chemist has formulated tranexamic acid into an SPF base before and request the stability data. This single question will quickly separate experienced suppliers from those who are agreeing to try something new on your budget.

Finding a manufacturer who checks all the boxes for a low-MOQ tranexamic acid SPF 50 sunscreen — FDA OTC compliance (US), CPSR capability (EU), low MOQ, tranexamic acid formulation experience, and reasonable timelines — requires a more targeted approach than browsing generic contract manufacturer directories, which are rarely curated for regulated sunscreen production. The first step is to be specific about your requirements before you start outreach. Know your target fill size, packaging format, MOQ, markets, and UV filter preference. Manufacturers and cosmetic chemists respond faster and more accurately to detailed briefs than vague requests. For the US market, qualified OTC sunscreen manufacturers must be registered with the FDA as drug establishment sites. You can search the FDA Establishment Registration database to verify a manufacturer's registration status before you sign anything. Facilities should also be able to provide a Certificate of Analysis for each batch, their CGMP compliance documentation, and references from other SPF brands they've produced. For EU-market products, look for manufacturers who routinely produce products requiring CPSR documentation and who have an in-house or preferred Responsible Person (RP) they work with for CPNP notification. Many EU co-packers offer this as a bundled service. The fastest way to connect with vetted suppliers in this niche is through AJ Cosmo Labs. The iOS app allows you to post a detailed brief for a private label tranexamic acid SPF 50 sunscreen, specifying your MOQ, markets, and formula requirements, and receive competitive responses from manufacturers who have already been reviewed by the platform. Unlike cold-emailing factories found on trade directories, the structured brief process on AJ Cosmo Labs filters for relevant, qualified suppliers and gives you direct messaging so you can ask technical screening questions before committing to samples or deposits. When evaluating any manufacturer response, always request: (1) a list of SPF SKUs they've manufactured commercially, (2) SPF test reports from an accredited testing lab, (3) their accelerated stability protocol and a sample report, and (4) a reference brand you can contact. Manufacturers who decline to share any of these before you've committed a deposit should be treated with caution. Regional trade shows like In-Cosmetics (global), Cosmoprof North America, and NYSCC Suppliers' Day are also strong hunting grounds for meeting OTC-capable manufacturers face to face, though the lead time from show contact to qualified quote is often 6–10 weeks, slower than a platform-based approach.

Claim strategy for a tranexamic acid SPF 50 sunscreen is one of the most nuanced areas of this product type, because you're operating at the intersection of drug labeling law (for the sunscreen component) and cosmetic marketing (for the brightening active). Getting it wrong can result in FDA warning letters, EU regulatory non-compliance, or consumer advertising challenges. In the United States, the Drug Facts panel is non-negotiable. It must follow the exact format and content requirements of 21 CFR 201.66. The active ingredient section lists only the FDA-approved UV filters and their concentrations. Tranexamic acid does not appear here. The purpose claim on the Drug Facts panel must state something like 'Sunscreen' or 'Helps prevent sunburn.' Disease claims (melasma treatment, for example) are not permitted on an OTC sunscreen label without an NDA. Your front-of-pack and marketing copy can reference brightening, dark spot reduction, and hyperpigmentation as cosmetic benefits, but these must be structured as cosmetic (appearance) claims, not drug claims. Do not use language like 'treats melasma,' 'reduces discoloration caused by hormonal changes,' or anything that implies a medical diagnosis or treatment. Permitted front-of-pack claims in the US context include: 'Visibly reduces dark spots,' 'Brightening SPF 50,' 'Broad spectrum SPF 50,' and 'Formulated with tranexamic acid.' These are appearance claims that do not trigger drug claim classification. Pair these with 'Helps prevent sunburn' and 'If used as directed with other sun protection measures, decreases the risk of skin cancer and early skin aging' — which are the only OTC-permitted disease-reduction claims for sunscreen. In the European Union, the EU Cosmetics Regulation Annex III limits tranexamic acid to 2% and classifies it as a cosmetic ingredient. The SPF claim must be supported by an in-vitro test result per COLIPA/ISO guidelines. EU sunscreen claims must follow the Commission Recommendation of 2006 on SPF labeling, which means SPF 50 falls into the 'Very High Protection' category and must be labeled accordingly. REACH considerations apply to ingredient transparency in the supply chain, but do not typically affect finished product labeling directly. In Canada, if the product is classified as a Natural Health Product or drug under Health Canada, SPF and brightening claims both fall under tighter scrutiny. Claims like 'reduces dark spots' may require clinical evidence to be submitted as part of the product license application. Document every claim with the substantiation it relies on before launch. For tranexamic acid's brightening efficacy, published peer-reviewed studies at 2–3% concentrations in comparable emulsion systems can serve as literature substantiation for cosmetic claims in many markets. For the SPF 50 claim, only your specific product's SPF test result counts.

Packaging choice for a private label tranexamic acid SPF 50 sunscreen affects cost, MOQ feasibility, formula stability, and consumer experience. At low order quantities, you also need to think carefully about what packaging formats your shortlisted manufacturers can actually run at 500–1,000 units without requiring a dedicated tooling investment. Tubes (laminate or aluminum, 30–50 mL) are the most common and MOQ-friendly format for SPF products. Most sunscreen co-packers run tube lines as their standard equipment, and laminate tube tooling (shoulder mold) for a new size can add $1,500 to $4,000 to your first-run costs, though many manufacturers have standard tube sizes you can use to avoid tooling fees entirely. Tubes protect the formula from light and oxygen exposure, which is important for both tranexamic acid stability and UV filter integrity. Airless pump bottles (30–50 mL) are growing in popularity for SPF serums and lightweight sunscreen fluids. They provide excellent oxidation protection and a premium consumer experience. However, airless pump equipment is less universally available at co-packers, and MOQs for airless filling sometimes start at 1,000–2,000 units. The per-unit packaging cost is higher ($0.90 to $2.50) compared to a laminate tube ($0.40 to $1.20). Jars are generally not recommended for SPF products. Repeated exposure to air and contamination from fingers can degrade UV filters and tranexamic acid over time, compromising both efficacy and shelf life. Regulatory bodies in the EU also flag jar-packaged sunscreens with higher scrutiny because application consistency (and therefore SPF efficacy as tested) is harder to achieve with fingers versus a pump or tube. Dropper bottles for SPF products introduce a dosing accuracy problem. The SPF efficacy test (both US in-vivo and EU in-vitro methods) assumes a standardized dose of 2 mg/cm² of skin surface area. A dropper makes consistent self-application at that dose difficult, which means the SPF 50 your testing lab measured may not be what your consumer achieves. Some regulators have raised concerns about this format for SPF products; if you use a dropper, ensure your manufacturer and regulatory counsel have addressed this in your CPSR or OTC documentation. For a first run at low MOQ, the safest, fastest, and most cost-effective choice is a 30 mL or 50 mL laminate tube using a stock shoulder size your manufacturer already runs. Once you've validated the SKU with initial sales, move to custom packaging at your second production run. AJ Cosmo Labs lets you specify packaging format preferences in your brief, helping match you with manufacturers whose existing line matches your format.